Fungal Infective Endocarditis Post Device Occlusion in Perimembranous Ventricular Septal Defect

Nadeem Sadiq, Intisar-Ul-Haq, Saima Rafique, Maad Ullah*, Khurram Akhtar, Hajira Akbar, Andaleeb Ara, Sana Imtiaz, Muhammad Asad Farhan, Tufail Ahmed

Armed Forces Institute of Cardiology/National Institute of Heart Diseases (AFIC/NIHD)/National University of Medical Science (NUMS) Rawalpindi Pakistan,
*Heart International Hospital, Rawalpindi Pakistan

ABSTRACT

Recent increase in deployment of trans-catheter devices such as septal or ductal occluding coils and devices has been a possible risk factor for infective endocarditis, predominantly in the initial post deployment period before endothelialization has ensued. Though a long-term study of trans-catheter Atrial Septal Defect (ASD) closure revealed no cases of Infective Endocarditis, some case reports of endocarditis in trans-catheter device closure of ASD, VSD and Patent ductus arteriosus (PDA) advocate that residual defect after device occlusion may be a factor in the risk for Infective Endocarditis. We herein describe the case of a 9-month-old female patient who underwent device closure for peri-membranous ventricular septal defect (VSD) and developed fungal infective endocarditis in early post occlusion period which was confirmed on blood culture. Despite treatment with appropriate antifungal as per sensitivity, clinical condition of the patient deteriorated and it was decided to manage her with surgical explantation of device and closure of defect.

Keywords: Device occlusion, Infective endocarditis, Transcatheter, Ventricular septal defect.

How to Cite This Article: Sadiq N, Haq I, Rafique S, Ullah M, Akhtar K, Akbar H, Ara A, Imtiaz S, Farhan M.A, Ahmed T. Fungal Infective Endocarditis Post Device Occlusion in Perimembranous Ventricular Septal Defect. Pak Armed Forces Med J 2022; 72(Suppl-3): S628-631.
DOI: https://doi.org/10.51253/pafmsj.e72iSUPPL-3.9549

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Ventricular septal defect (VSD) is one of the most common congenital heart defects.1,2 The traditional treatment was surgical closure which has a very low risk of morbidity and mortality.3 One of the most dreaded complications of this surgery is a complete atrioventricular block that is described in 0.7-3.1% of cases.3,4 Ever since the first attempt was made to close a VSD percutaneously in 1988 by Lock et al.

Transcatheter closure of peri membranous ventricular septal defects has been established as a procedure of choice in suitable candidates.5 A study done to compare surgical closure versus transcatheter closure of VSD has revealed transcatheter closure to be less invasive, having a shorter recovery time and requiring lesser hospital stay hence less morbidity. The incidence of complications in both were comparable.6

Main complications in VSD device closure are risk of dysrhythmias, hematoma of groin, residual shunt hemolysis requiring device removal, device embolization and infective endocarditis with infective endocarditis being a rare entity.7

CASE REPORT

Present case of a 9-month-old female patient who underwent device closure for perimembranous VSD measuring 5mm with 10mm lepus device, under fluoroscopic and echo guidance via antegrade approach. She was administered 50mg/kg of Cefotaxime before the procedure which was repeated 12 hours after the procedure. The procedure was successful and post procedure echo showed well profiled device with no residual leak. She was discharged on oral Cefixime for 72 hours and Loprin for 6 months.

She developed fever, and reported back to OPD after 72 hours. Her antibiotics were extended for 3 weeks, but the fever didn’t subside. She was febrile with a temperature of 39 degrees Celsius, heart rate was 150/min, respiratory rate was 30/min. A new onset systolic murmur grade 3/6 was heard at left lower sternal border. No visceromegaly, splinter hemorrhages and Roth spots were observed. She was admitted for additional investigations. Laboratory investigations revealed raised total leucocyte count, CRP and ESR. Blood cultures revealed Candida Tropi-calis sensitive to Fluconazole. She was thus started on oral fluconazole at 6 mg/kg/day. Echocardiography revealed 13 x 14 mm vegetations attached to tricuspid valve septal leaflet (Figure-1).

She was placed on IV fluconazole at 10 mg/kg/day. Her CRP increased further to 99 mg/dl and TLC to 22,000/mm³. HRCT chest showed multiple bilateral infective foci and the vegetation size increased markedly with severe Tricuspid regurgitation (Figure-2).
The device was removed using snare, and the defect was closed by an autologous pericardial patch using prolene suture.

Cardiac bypass time was 90 mins and cross clamp time was 68 mins. Tricuspid valve was salvaged. Patient was extubated within 24 hrs of surgery and had smooth post operative course. Trivial Tricuspid regurgitation documented post operatively with satisfactory patch closure of VSD.

**DISCUSSION**

Device closure is an effective way of managing VSDs, with a success rate approaching 94.8%, when different devices are used.\(^1,^8\) Main complications encountered being conduction disturbances, residual shunts, aortic regurgitation, embolization of device and hemolysis.\(^5\) Endocarditis is a very rare complication.\(^9\) Device associated endocarditis is not routinely reported in children after atrial and ventricular septal defect closure.\(^10,^11\)

The device might get infected by carrying microorganisms either during the procedure or after the procedure.\(^7\) It takes around 6 months for endothelialization to complete after device closure. Even temporary bacteremia during this time is capable of seeding the device with microbes.\(^7\) Nosocomial infection of the device may occur while doing the procedure. This highlights the importance of observing strict asepsis during the procedure itself and perhaps also proposes the use of infective endocarditis prophylaxis in these patients, after device implantation.

There is an increased risk of infective endocarditis in early childhood as reported by studies in children with congenital heart diseases and also in children from the general population that is probably caused by multiple factors. Many patients who have undergone surgery for their CHD lesions earlier in life, which seems to decrease the overall risk of IE, consequently having lower relative risk in older age groups. Indeed, data shows that IE risk is highest in children of ages 0 to 3 years. In this age group, the incidence of surgical procedures is not yet equal to those in general pediatric cardiology practice. Moreover, the use of intravascular catheters and devices at very young age might increase the risk of IE in these children.\(^12\)

Medical treatment of fungal IE is usually not successful except in the neonates with mural endocarditis.\(^11\) For majority of patients diagnosed with fungal IE, surgery along with antifungal medicines is needed. Consulting cardiology, infectious disease, and cardiac
surgery departments early on is suggested in these cases. Amphotericin B is the drug of choice for medical therapy, although its penetration in vegetations is sub-optimal. Although the Imidazoles (e.g., Fluconazole) are not proven to be effective in human fungal IE, long-term therapy with these agents is recommended for patients who are unable to undergo surgery and are having infections caused by these microorganisms.11,13

Cardiac surgery is required urgently at times and is imperative in patients with IE, but decision to perform surgical intervention is taken considering patient’s clinical condition and taking into account several other parameters. There are no special guidelines for surgical management of pediatric IE, they are mostly an extrapolation of recommendations for managing IE in adults. The most common indications for surgical intervention in IE are progressive valve dysfunction, congestive cardiac failure and embolic phenomena. It is very difficult to predict a patient’s risk for embolization, available data has no specific value of vegetation size on echocardiography which can be termed high risk. However, left-sided lesions involving anterior leaflet of the mitral valve if associated with S. aureus, seems associated with a very high risk for embolization. There are no pediatric recommendations for prophylactic surgery to avoid an embolic event keeping in view immediate and long-term risks of valve replacement in childhood. Other important problems for which early surgery is indicated include fungal endocarditis, perivalvular spread of infection, persistent bacteremia in spite of appropriate antibiotic therapy, ruptured sinus of Valsalva, or ventricular septal and myotic aneurysms.7,10

In our patient decision to proceed with surgical intervention was made due to suboptimal response to appropriate culture and sensitivity based antifungal treatment, clinical deterioration of patient along with increasing size of vegetations and worsening tricuspid regurgitation on echocardiography.

CONCLUSION

Endocarditis is although a very rare but possibly fatal complication of device closure of VSD. Strict aseptic measures along with appropriate prophylactic doses of antibiotic perioperatively are very important. Fever within 1-2 weeks time period following a transcatheter procedure should be treated as endocarditis until proven otherwise. The caretakers of patients should be advised to instantly report to medical facility if fever does not settle within 2 days. Early and timely session with cardiology, infectious disease, and cardiac surgery services leads to proper management and better clinical outcome in terms of morbidity and mortality.

ACKNOWLEDGEMENT

I am deeply grateful to my supervisor for his guidance, patience and support who provided insight and expertise that greatly assisted my research project. I also want to share my gratitude for COMDT Exec Dir AFIC/NHID and HOD R&D for their support and contribution in completion of the research paper.

Conflict of Interest: None.

Author’s Contribution:

Following authors have made substantial contributions to the manuscript as under:

NS: Manuscript writing, concept and editing
IUH Intellectual contribution, concept and final approval
SR: Concept, manuscript writing and critical review
MU: Review of article, formatting and critical review
KA: Proof reading, Intellectual contribution, final approval
HA: Proof reading, interpretation and article finalization
AA: Final approval, proof reading and critical review
SI: Intellectual contribution, concept and final approval
MAF: Review of article, formatting and critical review
TA: Final approval, proof reading and critical review

Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

REFERENCES

1. Arora R, Trehan V, Kumar A, Kalra GS, Nigam M. Transcatheter closure of congenital ventricular septal defects: experience with various devices. J Interv Cardiol 2003; 16(1): 83-91.
2. Jang SI, Kim SH. Echocardiographic Classification and Guidance for Transcatheter Closure of Ventricular Septal Defect. J Cardiovasc Imaging 2021; 29(4): 327-330.
3. Azab S, El-Shahawy H, Samy A, Mahdy W. Permanent complete heart block following surgical closure of isolated ventricular septal defect. Egypt J Chest Dis Tuber-cul 2013; 62(3): 529-533.
4. Andersen H, de Leval MR, Tsang VT, Elliott MJ. Is complete heart block after surgical closure of ventricular septum defects still an issue? Ann Thorac Surg 2006; 82(3): 945-956.
5. Khoshhal SQ, Al-Mutaifi MB, Alnajjar AA, Morsy MM, Salem SS, Al-Muhaya M, et al. Transcatheter device closure of ventricular septal defects in children: a retrospective study at a single cardiac center. Ann Saudi Med 2020; 40(5): 396-402.
6. Rao PS, Harris AD. Recent advances in managing septal defects: ventricular septal defects and atrioventricular septal defects. F1000Res 2018; 7:F1000 Faculty Rev-498. doi: 10.12688/f1000research.14102.1.
7. Rashani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, et al. Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. Circulation 2013; 128(13): 1412-1419.
Perimembranous Ventricular Septal Defect

8. Scheuerman O, Bruckheimer E, Marcus N, Hoffer V. Endocarditis after closure of ventricular septal defect by transcatheter device. Pediatrics 2006; 117(6): 1256-1258.
9. Kassis I, Khatib I, Khoury A, Le TP, Lorber A. Kingella endocarditis after closure of ventricular septal defect with a transcatheter device. Pediatr Infect Dis J 2012; 31(1): 105-106.
10. El-Sisi AM, Menaissy YM, Bekheet SA. Infective endocarditis following coil occlusion of perimembranous ventricular septal defect with the Nit-Occlud (R) Le device. Ann Pediatr Cardiol 2016; 9(1): 59-61.
11. Meena DS, Kumar D, Agarwal M. Clinical features, diagnosis and treatment outcome of fungal endocarditis: A systematic review of reported cases. Mycoses 2022; 65(3): 294-302.
12. RM, VR, Nambi PS, Ramakrishnan B, Gopalakrishnan R, Sathymurthy. Profile of infective endocarditis: at a tertiary care referral centre. J Assoc Physicians India 2018; 66(6): 60-65.
13. Siciliano RF, Guandalro DM, Sejas ONE, Ignoto BG, Caramelli B, Mansur AJ, et al. Outcomes in patients with fungal endocarditis: A multicenter observational cohort study. Int J Infect Dis 2018; 48-52.